Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters










Publication year range
2.
Naunyn Schmiedebergs Arch Pharmacol ; 391(11): 1191-1202, 2018 11.
Article in English | MEDLINE | ID: mdl-30054681

ABSTRACT

Transient receptor potential cation channel subfamily M member 4 (TRPM4) has been shown to play a key role in detrusor contractility under physiological conditions. In this study, we investigated the potential role of TRPM4 in detrusor overactivity following spinal cord transection (SCT) in mice. TRPM4 expression and function were evaluated in bladder tissue with or without the mucosa from spinal intact (SI) and SCT female mice (T8-T9 vertebra; 1-28 days post SCT) using PCR, western blot, immunohistochemistry, and muscle strip contractility techniques. TRPM4 was expressed in the urothelium (UT) and detrusor smooth muscle (DSM) and was upregulated after SCT. Expression levels peaked 3-7 days post SCT in both the UT and DSM. Pharmacological block of TRPM4 with the antagonist, 9-Phenanthrol (30 µM) greatly reduced spontaneous phasic activity that developed after SCT, regardless of the presence or absence of the mucosa. Detrusor overactivity following spinal cord injury leads to incontinence and/or renal impairment and represents a major health problem for which current treatments are not satisfactory. Augmented TRPM4 expression in the bladder after chronic SCT supports the hypothesis that TRPM4 channels play a role in DSM overactivity following SCT. Inhibition of TRPM4 may be beneficial for improving detrusor overactivity in SCI.


Subject(s)
Muscle, Smooth/physiology , Spinal Cord Injuries , TRPM Cation Channels/physiology , Urinary Bladder, Overactive/physiopathology , Urinary Bladder/physiology , Animals , Female , Mice, Inbred C57BL , Muscle Contraction/physiology , Urothelium/physiology
3.
Front Syst Neurosci ; 12: 13, 2018.
Article in English | MEDLINE | ID: mdl-29706873

ABSTRACT

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disease of unknown etiology. A naturally occurring disease termed feline interstitial cystitis (FIC) reproduces many features of IC/BPS patients. To gain insights into mechanisms underlying IC/BPS, we investigated pathological changes in the lamina propria (LP) of the bladder and proximal urethra in cats with FIC, using histological and molecular methods. Compared to control cat tissue, we found an increased number of de-granulated mast cells, accumulation of leukocytes, increased cyclooxygenase (COX)-1 expression in the bladder LP, and increased COX-2 expression in the urethra LP from cats with FIC. We also found increased suburothelial proliferation, evidenced by mucosal von Brunn's nests, neovascularization and alterations in elastin content. Scanning electron microscopy revealed normal appearance of the superficial urethral epithelium, including the neuroendocrine cells (termed paraneurons), in FIC urethrae. Together, these histological findings suggest the presence of chronic inflammation of unknown origin leading to tissue remodeling. Since the mucosa functions as part of a "sensory network" and urothelial cells, nerves and other cells in the LP are influenced by the composition of the underlying tissues including the vasculature, the changes observed in the present study may alter the communication of sensory information between different cellular components. This type of mucosal signaling can also extend to the urethra, where recent evidence has revealed that the urethral epithelium is likely to be part of a signaling system involving paraneurons and sensory nerves. Taken together, our data suggest a more prominent role for chronic inflammation and tissue remodeling than previously thought, which may result in alterations in mucosal signaling within the urinary bladder and proximal urethra that may contribute to altered sensations and pain in cats and humans with this syndrome.

4.
Semin Immunopathol ; 40(3): 261-279, 2018 05.
Article in English | MEDLINE | ID: mdl-29582112

ABSTRACT

Intense research has focused on the involvement of the nervous system in regard to cellular mechanisms underlying neurogenic inflammation in the pelvic viscera. Evidence supports the neural release of inflammatory factors, trophic factors, and neuropeptides in the initiation of inflammation. However, more recently, non-neuronal cells including epithelia, endothelial, mast cells, and paraneurons are likely important participants in nervous system functions. For example, the urinary bladder urothelial cells are emerging as key elements in the detection and transmission of both physiological and nociceptive stimuli in the lower urinary tract. There is mounting evidence that these cells are involved in sensory mechanisms and can release mediators. Further, localization of afferent nerves next to the urothelium suggests these cells may be targets for transmitters released from bladder nerves and that chemicals released by urothelial cells may alter afferent excitability. Modifications of this type of communication in a number of pathological conditions can result in altered release of epithelial-derived mediators, which can activate local sensory nerves. Taken together, these and other findings highlighted in this review suggest that neurogenic inflammation involves complex anatomical and physiological interactions among a number of cell types in the bladder wall. The specific factors and pathways that mediate inflammatory responses in both acute and chronic conditions are not well understood and need to be further examined. Elucidation of mechanisms impacting on these pathways may provide insights into the pathology of various types of disorders involving the pelvic viscera.


Subject(s)
Neurogenic Inflammation/metabolism , Urinary Bladder/metabolism , Urothelium/metabolism , Animals , Humans
5.
Biomech Model Mechanobiol ; 17(2): 403-417, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29039043

ABSTRACT

In this work, we re-evaluated long-standing conjectures as to the source of the exceptionally large compliance of the bladder wall. Whereas these conjectures were based on indirect measures of loading mechanisms, in this work we take advantage of advances in bioimaging to directly assess collagen fibers and wall architecture during biaxial loading. A custom biaxial mechanical testing system compatible with multiphoton microscopy was used to directly measure the layer-dependent collagen fiber recruitment in bladder tissue from 9 male Fischer rats (4 adult and 5 aged). As for other soft tissues, the bladder loading curve was exponential in shape and could be divided into toe, transition and high stress regimes. The relationship between collagen recruitment and loading curves was evaluated in the context of the inner (lamina propria) and outer (detrusor smooth muscle) layers. The large extensibility of the bladder was found to be possible due to folds in the wall (rugae) that provide a mechanism for low resistance flattening without any discernible recruitment of collagen fibers throughout the toe regime. For more extensible bladders, as the loading extended into the transition regime, a gradual coordinated recruitment of collagen fibers between the lamina propria layer and detrusor smooth muscle layer was found. A second important finding was that wall extensibility could be lost by premature recruitment of collagen in the outer wall that cut short the toe region. This change was correlated with age. This work provides, for the first time, a mechanistic understanding of the role of collagen recruitment in determining bladder extensibility and capacitance.


Subject(s)
Collagen/metabolism , Urinary Bladder/metabolism , Animals , Biomechanical Phenomena , Compliance , Male , Microscopy, Fluorescence, Multiphoton , Mucous Membrane/metabolism , Muscle, Smooth/metabolism , Rats, Inbred F344 , Stress, Mechanical , Weight-Bearing
6.
eNeuro ; 4(3)2017.
Article in English | MEDLINE | ID: mdl-28560313

ABSTRACT

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic voiding disorder that presents with pain in the urinary bladder and surrounding pelvic region. A growing body of evidence suggests that an increase in the permeability of the urothelium, the epithelial barrier that lines the interior of the bladder, contributes to the symptoms of IC/BPS. To examine the consequence of increased urothelial permeability on pelvic pain and afferent excitability, we overexpressed in the urothelium claudin 2 (Cldn2), a tight junction (TJ)-associated protein whose message is significantly upregulated in biopsies of IC/BPS patients. Consistent with the presence of bladder-derived pain, rats overexpressing Cldn2 showed hypersensitivity to von Frey filaments applied to the pelvic region. Overexpression of Cldn2 increased the expression of c-Fos and promoted the activation of ERK1/2 in spinal cord segments receiving bladder input, which we conceive is the result of noxious stimulation of afferent pathways. To determine whether the mechanical allodynia observed in rats with reduced urothelial barrier function results from altered afferent activity, we examined the firing of acutely isolated bladder sensory neurons. In patch-clamp recordings, about 30% of the bladder sensory neurons from rats transduced with Cldn2, but not controls transduced with GFP, displayed spontaneous activity. Furthermore, bladder sensory neurons with tetrodotoxin-sensitive (TTX-S) action potentials from rats transduced with Cldn2 showed hyperexcitability in response to suprathreshold electrical stimulation. These findings suggest that as a result of a leaky urothelium, the diffusion of urinary solutes through the urothelial barrier sensitizes bladders afferents, promoting voiding at low filling volumes and pain.


Subject(s)
Neurons, Afferent/metabolism , Pelvic Pain/metabolism , Tight Junctions/metabolism , Urinary Bladder/innervation , Urinary Bladder/metabolism , Urothelium/metabolism , Action Potentials , Animals , Claudins/metabolism , Cystitis/metabolism , Cystitis/pathology , Disease Models, Animal , Female , Hyperalgesia/metabolism , Hyperalgesia/pathology , MAP Kinase Signaling System/physiology , Neural Pathways/metabolism , Neural Pathways/pathology , Neurons, Afferent/pathology , Patch-Clamp Techniques , Pelvic Pain/pathology , Permeability , Random Allocation , Rats, Sprague-Dawley , Single-Blind Method , Spinal Cord/metabolism , Spinal Cord/pathology , Tight Junctions/pathology , Urinary Bladder/pathology , Urothelium/pathology
7.
Am J Physiol Renal Physiol ; 313(1): F85-F102, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28331065

ABSTRACT

The basal, intermediate, and superficial cell layers of the urothelium undergo rapid and complete recovery following acute injury; however, the effects of chronic injury on urothelial regeneration have not been well defined. To address this discrepancy, we employed a mouse model to explore urothelial changes in response to spinal cord injury (SCI), a condition characterized by life-long bladder dysfunction. One day post SCI there was a focal loss of umbrella cells, which are large cells that populate the superficial cell layer and normally express uroplakins (UPKs) and KRT20, but not KRT5, KRT14, or TP63. In response to SCI, regions of urothelium devoid of umbrella cells were replaced with small superficial cells that lacked KRT20 expression and appeared to be derived in part from the underlying intermediate cell layer, including cells positive for KRT5 and TP63. We also observed KRT14-positive basal cells that extended thin cytoplasmic extensions, which terminated in the bladder lumen. Both KRT14-positive and KRT14-negative urothelial cells proliferated 1 day post SCI, and by 7 days, cells in the underlying lamina propria, detrusor, and adventitia were also dividing. At 28 days post SCI, the urothelium appeared morphologically patent, and the number of proliferative cells decreased to baseline levels; however, patches of small superficial cells were detected that coexpressed UPKs, KRT5, KRT14, and TP63, but failed to express KRT20. Thus, unlike the rapid and complete restoration of the urothelium that occurs in response to acute injuries, regions of incompletely differentiated urothelium were observed even 28 days post SCI.


Subject(s)
Cell Proliferation , Regeneration , Spinal Cord Injuries/pathology , Urinary Bladder/pathology , Urothelium/pathology , Animals , Biomarkers/metabolism , Disease Models, Animal , Female , Keratin-14/metabolism , Keratin-15/metabolism , Keratin-20/metabolism , Mice, Inbred C57BL , Phenotype , Phosphoproteins/metabolism , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/physiopathology , Time Factors , Trans-Activators/metabolism , Urinary Bladder/innervation , Urinary Bladder/metabolism , Urinary Bladder/ultrastructure , Urothelium/innervation , Urothelium/metabolism , Urothelium/ultrastructure
8.
Naunyn Schmiedebergs Arch Pharmacol ; 390(2): 163-173, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27889808

ABSTRACT

The purpose of this study was to determine feasibility of a novel therapeutic approach to drug-induced voiding after spinal cord injury (SCI) using a well-characterized, peptide, neurokinin 2 receptor (NK2 receptor) agonist, Lys5, MeLeu9, Nle10-NKA(4-10) (LMN-NKA). Cystometry and colorectal pressure measurements were performed in urethane-anesthetized, intact, and acutely spinalized female rats. Bladder pressure and voiding were monitored in response to intravenous LMN-NKA given with the bladder filled to 70% capacity. LMN-NKA (0.1-300 µg/kg) produced dose-dependent, rapid (<60 s), short-duration (<15 min) increases in bladder pressure. In intact rats, doses above 0.3-1 µg/kg induced urine release (voiding efficiency of ~70% at ≥1 µg/kg). In spinalized rats, urine release required higher doses (≥10 µg/kg) and was less efficient (30-50%). LMN-NKA (0.1-100 µg/kg) also produced dose-dependent increases in colorectal pressure. No tachyphylaxis was observed, and the responses were blocked by an NK2 receptor antagonist (GR159897, 1 mg/kg i.v.). No obvious cardiorespiratory effects were noted. These results suggest that rapid-onset, short-duration, drug-induced voiding is possible in acute spinal and intact rats with intravenous administration of an NK2 receptor agonist. Future challenges remain in regard to finding alternative routes of administration that produce clinically significant voiding, multiple times per day, in animal models of chronic SCI.


Subject(s)
Colon/drug effects , Gastrointestinal Motility/drug effects , Muscle Contraction/drug effects , Neurokinin A/analogs & derivatives , Peptide Fragments/pharmacology , Spinal Cord Injuries/drug therapy , Urinary Bladder/drug effects , Urodynamics/drug effects , Animals , Colon/innervation , Disease Models, Animal , Dose-Response Relationship, Drug , Feasibility Studies , Female , Indoles/pharmacology , Neurokinin A/pharmacology , Piperidines/pharmacology , Pressure , Rats, Sprague-Dawley , Receptors, Neurokinin-2/drug effects , Receptors, Neurokinin-2/metabolism , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/physiopathology , Time Factors , Urinary Bladder/innervation
9.
Am J Physiol Renal Physiol ; 309(12): F1070-81, 2015 Dec 15.
Article in English | MEDLINE | ID: mdl-26423859

ABSTRACT

Changes in the urothelial barrier are observed in patients with cystitis, but whether this leads to inflammation or occurs in response to it is currently unknown. To determine whether urothelial barrier dysfunction is sufficient to promote cystitis, we employed in situ adenoviral transduction to selectively overexpress the pore-forming tight junction-associated protein claudin-2 (CLDN-2). As expected, the expression of CLDN-2 in the umbrella cells increased the permeability of the paracellular route toward ions, but not to large organic molecules. In vivo studies of bladder function revealed higher intravesical basal pressures, reduced compliance, and increased voiding frequency in rats transduced with CLDN-2 vs. controls transduced with green fluorescent protein. While the integrity of the urothelial barrier was preserved in the rats transduced with CLDN-2, we found that the expression of this protein in the umbrella cells initiated an inflammatory process in the urinary bladder characterized by edema and the presence of a lymphocytic infiltrate. Taken together, these results are consistent with the notion that urothelial barrier dysfunction may be sufficient to trigger bladder inflammation and to alter bladder function.


Subject(s)
Cell Membrane Permeability/physiology , Claudins/metabolism , Cystitis/metabolism , Urothelium/metabolism , Animals , Claudins/genetics , Cystitis/pathology , Epithelial Cells/metabolism , Female , Muscle, Smooth/metabolism , Muscle, Smooth/pathology , Rats, Sprague-Dawley , Tight Junctions/metabolism , Tight Junctions/pathology , Urothelium/pathology
10.
J Vis Exp ; (90): e51807, 2014 Aug 18.
Article in English | MEDLINE | ID: mdl-25178111

ABSTRACT

We describe an in vitro method to measure bladder smooth muscle contractility, and its use for investigating physiological and pharmacological properties of the smooth muscle as well as changes induced by pathology. This method provides critical information for understanding bladder function while overcoming major methodological difficulties encountered in in vivo experiments, such as surgical and pharmacological manipulations that affect stability and survival of the preparations, the use of human tissue, and/or the use of expensive chemicals. It also provides a way to investigate the properties of each bladder component (i.e. smooth muscle, mucosa, nerves) in healthy and pathological conditions. The urinary bladder is removed from an anesthetized animal, placed in Krebs solution and cut into strips. Strips are placed into a chamber filled with warm Krebs solution. One end is attached to an isometric tension transducer to measure contraction force, the other end is attached to a fixed rod. Tissue is stimulated by directly adding compounds to the bath or by electric field stimulation electrodes that activate nerves, similar to triggering bladder contractions in vivo. We demonstrate the use of this method to evaluate spontaneous smooth muscle contractility during development and after an experimental spinal cord injury, the nature of neurotransmission (transmitters and receptors involved), factors involved in modulation of smooth muscle activity, the role of individual bladder components, and species and organ differences in response to pharmacological agents. Additionally, it could be used for investigating intracellular pathways involved in contraction and/or relaxation of the smooth muscle, drug structure-activity relationships and evaluation of transmitter release. The in vitro smooth muscle contractility method has been used extensively for over 50 years, and has provided data that significantly contributed to our understanding of bladder function as well as to pharmaceutical development of compounds currently used clinically for bladder management.


Subject(s)
Drug Evaluation, Preclinical/methods , Muscle, Smooth/drug effects , Urinary Bladder/drug effects , Animals , Female , In Vitro Techniques , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle, Smooth/innervation , Muscle, Smooth/physiology , Rats , Rats, Sprague-Dawley , Urinary Bladder/innervation , Urinary Bladder/physiology
11.
Auton Neurosci ; 183: 58-65, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24656892

ABSTRACT

In vivo experiments in a diabetic rat model revealed compromised nitrergic urethral relaxations and increased sensitivity to adrenergic agonists. This study evaluated contractile and relaxation properties of urethral smooth muscle after streptozotocin (STZ)-induced diabetes, in vitro, with the aim of determining whether in vivo deficiencies are related to smooth muscle dysfunction. Urethral tissue was collected from adult female Sprague-Dawley rats naive, STZ-treated, vehicle-treated and sucrose-fed at 9-12 week post treatment. Strips from proximal, mid, and distal urethra were placed in tissue baths and stimulated using electric field stimulation (EFS) and pharmacological agents. nNOS staining was evaluated using immunohistochemistry. Phenylephrine (PE, 10µM) contracted all urethral strips with the highest amplitude in mid urethra, in all treatment groups. Likewise, EFS-induced relaxation amplitudes were larger and were observed more frequently in mid urethra. Relaxations were inhibited by the NOS inhibitor, L-NAME (1-100µM). Sodium nitroprusside (0.01-1µM), an NO donor, reversed PE-induced contractions. No statistical differences were observed between treatment groups with respect to any parameters. Qualitative immunohistochemistry showed no differences in the urethral nNOS innervation patterns across the treatment groups. In summary, nitrergic relaxations and adrenergic-induced contractions in the isolated diabetic rat urethra display similar properties to controls, suggesting no dysfunction on the nitrergic or alpha1 adrenergic receptor function in the smooth muscle. This further implies that compromised urethral relaxation and increased adrenergic agonist sensitivity observed in vivo in this model may be due to the disruption of neural signaling between the urethra and the spinal cord, or within the CNS.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle, Smooth/drug effects , Muscle, Smooth/physiopathology , Animals , Electric Stimulation , Enzyme Inhibitors/pharmacology , Female , Immunohistochemistry , In Vitro Techniques , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase Type I/antagonists & inhibitors , Nitric Oxide Synthase Type I/metabolism , Nitroprusside/pharmacology , Phenylephrine/pharmacology , Rats, Sprague-Dawley , Sympathomimetics/pharmacology , Urethra
12.
Life Sci ; 100(1): 35-44, 2014 Mar 28.
Article in English | MEDLINE | ID: mdl-24496039

ABSTRACT

AIMS: Bombesin receptors (BB receptors) and bombesin related peptides are expressed in the lower urinary tract of rodents. Here we investigated whether in vivo activation of BB receptors can contract the urinary bladder and facilitate micturition in sham rats and in a diabetic rat model of voiding dysfunction. MATERIAL AND METHODS: In vivo cystometry experiments were performed in adult female Sprague-Dawley rats under urethane anesthesia. Diabetes was induced by streptozotocin (STZ; 65mg/kg, i.p.) injection. Experiments were performed 9 and 20weeks post STZ-treatment. Drugs included neuromedin B (NMB; BB1 receptor preferring agonist), and gastrin-releasing peptide (GRP; BB2 receptor preferring agonist). KEY FINDINGS: NMB and GRP (0.01-100µg/kg in sham rats; 0.1-300µg/kg in STZ-treated rats, i.v.) increased micturition frequency, bladder contraction amplitude and area under the curve dose dependently in both sham and STZ-treated rats. In addition, NMB (3, 10µg/kg i.v.) triggered voiding in >80% of STZ-treated rats when the bladder was filled to a sub-threshold voiding volume. NMB and GRP increased mean arterial pressure and heart rate at the highest doses, 100 and 300µg/kg. SIGNIFICANCE: Activation of bombesin receptors facilitated neurogenic bladder contractions in vivo. Single applications of agonists enhanced or triggered voiding in sham rats as well as in the STZ-treated rat model of diabetic voiding dysfunction. These results suggest that BB receptors may be targeted for drug development for conditions associated with poor detrusor contraction such as an underactive bladder condition.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Receptors, Bombesin/physiology , Urinary Bladder/drug effects , Animals , Diabetes Mellitus, Experimental/metabolism , Drug Evaluation, Preclinical , Female , Gastrin-Releasing Peptide/pharmacology , Muscle Contraction , Neurokinin B/analogs & derivatives , Neurokinin B/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Bombesin/agonists , Urinary Bladder/metabolism , Urinary Bladder/physiopathology , Urination/drug effects
13.
Neuropeptides ; 47(5): 305-13, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24054546

ABSTRACT

AIMS: Bombesin receptors (BB receptors) and/or bombesin related peptides are expressed in the lower urinary tract, though their function and distribution in different species is largely unknown. This study examines whether BB receptor agonists can contract bladder smooth muscle in rats, mice, pigs and humans. METHODS: Bladder strips were placed in tissue baths for in vitro contractility. Neuronally evoked contractions were elicited using electric field stimulation (EFS). Effects of the BB receptor agonists, neuromedin B (NMB; BB1 receptor agonist) and gastrin-releasing peptide (GRP; BB2 receptor agonist) on baseline tone and EFS-induced contractions were monitored. RESULTS: In rat and human bladder strips, NMB and GRP (10(-11)-10(-6)M) increased EFS-induced contractions in a concentration dependent manner. In these species, NMB and GRP also increased baseline tension. In mouse and pig bladder strips, NMB and GRP (10(-8)-3×10(-6)M) had no effects on either parameter. CONCLUSIONS: These data suggest that bombesin receptors BB receptor 1 and/or BB receptor 2 increase bladder contractions in rat and human. The site of action of these receptors may be pre- and/or post-synaptic, increasing release of transmitters or enhancing smooth muscle excitability, respectively. Thus, BB1 receptor and/or BB2 receptor may offer therapeutic targets for voiding dysfunction associated with impaired bladder contractility; however, species differences must be considered when studying these receptors. Part of this work was published in an abstract form at the SFN meeting New Orleans, 2012.


Subject(s)
Receptors, Bombesin/metabolism , Urinary Bladder/physiology , Adult , Aged , Animals , Electric Stimulation , Female , Gastrin-Releasing Peptide/pharmacology , Humans , In Vitro Techniques , Male , Mice , Mice, Inbred C57BL , Middle Aged , Neurokinin B/analogs & derivatives , Neurokinin B/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Bombesin/agonists , Swine , Urinary Bladder/drug effects , Urinary Bladder/metabolism
14.
PLoS One ; 8(9): e73771, 2013.
Article in English | MEDLINE | ID: mdl-24040064

ABSTRACT

Time- and vehicle-related variability of bladder and urethral rhabdosphincter (URS) activity as well as cardiorespiratory and blood chemistry values were examined in the acetic acid-induced bladder irritation model in α-chloralose-anesthetized female cats. Additionally, bladder and urethra were evaluated histologically using Mason trichrome and toluidine blue staining. Urodynamic, cardiovascular and respiratory parameters were collected during intravesical saline infusion followed by acetic acid (0.5%) to irritate the bladder. One hour after starting acetic acid infusion, a protocol consisting of a cystometrogram, continuous infusion-induced rhythmic voiding contractions, and a 5 min "quiet period" (bladder emptied without infusion) was precisely repeated every 30 minutes. Administration of vehicle (saline i.v.) occurred 15 minutes after starting each of the first 7 cystometrograms and duloxetine (1mg/kg i.v.) after the 8(th). Acetic acid infusion into the bladder increased URS-EMG activity, bladder contraction frequency, and decreased contraction amplitude and capacity, compared to saline. Bladder activity and URS activity stabilized within 1 and 2 hours, respectively. Duloxetine administration significantly decreased bladder contraction frequency and increased URS-EMG activity to levels similar to previous reports. Cardiorespiratory parameters and blood gas levels remained consistent throughout the experiment. The epithelium of the bladder and urethra were greatly damaged and edema and infiltration of neutrophils in the lamina propria of urethra were observed. These data provide an ample evaluation of the health of the animals, stability of voiding function and appropriateness of the model for testing drugs designed to evaluate lower urinary tract as well as cardiovascular and respiratory systems function.


Subject(s)
Anesthesia/methods , Chloralose/pharmacology , Urinary Bladder Diseases/physiopathology , Urinary Bladder/physiopathology , Acetic Acid , Adrenergic Uptake Inhibitors/administration & dosage , Adrenergic Uptake Inhibitors/pharmacology , Animals , Blood Pressure/drug effects , Cats , Chloralose/administration & dosage , Disease Models, Animal , Duloxetine Hydrochloride , Electromyography , Female , Heart Rate/drug effects , Humans , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/pharmacology , Muscle Contraction/drug effects , Respiration/drug effects , Thiophenes/administration & dosage , Thiophenes/pharmacology , Time Factors , Urethra/drug effects , Urethra/physiopathology , Urinary Bladder/drug effects , Urinary Bladder Diseases/chemically induced , Urination/drug effects
15.
Auton Neurosci ; 176(1-2): 70-7, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23511063

ABSTRACT

This study evaluated the effects of a 5-HT4 agonist, cisapride, on neuronally evoked smooth muscle responses in bladder, urethra and ileum and compared these effects with those of an acetylcholinesterase inhibitor, distigmine. Electrical field stimulation (EFS) was applied to human bladder and ileum smooth muscle strips from human organ transplant donors and to urethral strips from prostatectomy patients, to evoke neuronally mediated smooth muscle responses. EFS induced contractions in bladder and mixed responses, consisting of contractions and relaxations, in urethra and ileum. Relaxations were mediated by nitric oxide while contractions were partially cholinergic (i.e. atropine sensitive). This atropine sensitive component amounted to~95% in bladder and ~75% in ileum, and it was enhanced by distigmine in a concentration dependent manner (0.1-3 µM; ~100-600% increase in bladder and ~50-250% increase in ileum). Cisapride (0.0003-1 µM) also enhanced bladder contractions (~75-100% increase) but had no effect on urethral contractions or relaxations, and modestly enhanced ileum contractions (~10-40% increase). Facilitatory effects of cisapride were reversed by the specific 5-HT4 receptor antagonist, SB-203186 (3 µM), but were resistant to repeated washing in the bladder. These data indicate that 5-HT4 receptor agonists enhanced EFS-induced contractions in bladder and ileum without an effect on urethra and suggest that it may be possible to enhance bladder activity with a dose of cisapride that is at, or below, those producing gastrointestinal (GI) effects. Although distigmine's maximal facilitation of bladder and GI tract function was greater than that of cisapride, at clinically relevant concentrations cisapride showed much greater efficacy.


Subject(s)
Cisapride/pharmacology , Evoked Potentials/drug effects , Ileum/physiology , Muscle Contraction/physiology , Neurons/physiology , Receptors, Serotonin, 5-HT4/physiology , Serotonin 5-HT4 Receptor Agonists/pharmacology , Urethra/physiology , Adult , Aged , Electric Stimulation/methods , Evoked Potentials/physiology , Female , Humans , Ileum/drug effects , Male , Middle Aged , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Neurons/drug effects , Organ Culture Techniques , Urethra/drug effects , Urinary Bladder
16.
Life Sci ; 92(12): 733-9, 2013 Apr 09.
Article in English | MEDLINE | ID: mdl-23399698

ABSTRACT

AIMS: To determine if the muscarinic agonist, bethanechol, inhibits the non-cholinergic, atropine-resistant (i.e. putatively purinergic) component of naturally occurring (i.e. reflexogenic) bladder contractions in vivo in the rat, as previously described in vitro. Our second aim was to determine if elevation of endogenous acetylcholine (ACh) with distigmine, an acetylcholine esterase (AChE) inhibitor, could also inhibit non-cholinergic component of reflexogenic bladder contractions. MAIN METHODS: Cystometry was performed in urethane anesthetized adult female Sprague Dawley rats. The nonselective muscarinic receptor (mAChR) antagonist, atropine, was administered intravenously (i.v.) before and after i.v. administration of the non-selective mAChR agonist, bethanechol, the AChE inhibitor, distigmine or the neurokinin receptor 2 agonist, [ßAla(8)]-Neurokinin A(4-10). Intermicturition interval (IMI), bladder contraction amplitude (BCA), postvoid bladder pressure (PVBP), and voiding efficiency (VE) were measured. KEY FINDINGS: Atropine (0.4 mg/kg; n=11 rats) delivered as the first drug, had insignificant effects on BCA (~15% reduction) or PVBP (~15% increase) and weakly reduced IMI and VE by ~40% (p<0.05) relative to vehicle. Bethanechol and distigmine on their own produced excitatory effects on bladder activity, consistent with mAChR activation. Unexpectedly atropine, administered after bethanechol or after distigmine but not after [ßAla(8)]-Neurokinin A(4-10), completely blocked bladder activity for 3-10 min. Partial recovery of bladder activity occurred after that time, but BCA, IMI, and VE remained significantly reduced and PVBP remained significantly increased. SIGNIFICANCE: Activation of mAChRs by an exogenous agonist or elevation of endogenous ACh levels by an AChE inhibitor inhibits the non-cholinergic, atropine-resistant, component of reflexogenic bladder contractions in vivo.


Subject(s)
Bethanechol/pharmacology , Muscarinic Agonists/pharmacology , Muscle Contraction/drug effects , Receptors, Muscarinic/metabolism , Urinary Bladder/drug effects , Acetylcholine/metabolism , Animals , Atropine/pharmacology , Cholinesterase Inhibitors/pharmacology , Female , Muscarinic Antagonists/pharmacology , Pyridinium Compounds/pharmacology , Rats , Rats, Sprague-Dawley , Urinary Bladder/physiology
17.
Neurourol Urodyn ; 30(8): 1666-74, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21717503

ABSTRACT

AIMS: During postnatal development large amplitude spontaneous activity of the neonatal rat bladder changes to a low amplitude adult pattern of activity that leads to improved storage function. Previously, we have shown that spontaneous activity in neonatal rat bladder strips is inhibited by activation of the nitric oxide (NO)-cGMP signaling pathway. In the present experiments we determined if this inhibitory pathway is altered during postnatal development or spinal cord injury. METHODS: Baseline tone and amplitude and frequency of spontaneous contractions were measured in bladder strips from male or female neonatal (days 10-21), juvenile (days 24-39) and adult female spinal cord intact or chronic spinal cord injured Sprague-Dawley rats. RESULTS: The inhibitory effects of an NO donor (SNAP) and a PDE-5 inhibitor (zaprinast) on spontaneous activity of bladder strips decreased during postnatal development, while an inhibitory effect of 8-bromo-cGMP, which was blocked by a protein kinase G inhibitor, was detected at all ages tested. However, the effect of NO-cGMP signaling to reduce baseline tone emerged during postnatal development. The inhibition induced by the NO donor was blocked by an inhibitor of soluble guanylyl cyclase (sGC). Chronic spinal cord injury (cSCI), which causes the re-emergence of a neonatal-like pattern of spontaneous activity, did not restore sensitivity to NO-mediated inhibition in adult rat bladders. CONCLUSIONS: These data indicate that while cGMP signaling inhibits activity in young and adult bladders as well as after cSCI, there is a developmental decrease in the sensitivity of bladder to NO-mediated inhibition.


Subject(s)
Nitric Oxide/metabolism , Signal Transduction , Spinal Cord Injuries/metabolism , Urinary Bladder/metabolism , Urodynamics , Age Factors , Animals , Animals, Newborn , Cyclic GMP/metabolism , Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic GMP-Dependent Protein Kinases/metabolism , Disease Models, Animal , Female , Guanylate Cyclase/antagonists & inhibitors , Guanylate Cyclase/metabolism , Male , Nitric Oxide Donors/pharmacology , Phosphodiesterase 5 Inhibitors/pharmacology , Protein Kinase Inhibitors/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Receptors, Cytoplasmic and Nuclear/metabolism , Signal Transduction/drug effects , Soluble Guanylyl Cyclase , Spinal Cord Injuries/physiopathology , Urinary Bladder/drug effects , Urinary Bladder/growth & development , Urinary Bladder/physiopathology , Urodynamics/drug effects
18.
Neurourol Urodyn ; 30(1): 144-50, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21046653

ABSTRACT

AIMS: To investigate the distribution of beta-3 adrenergic receptors (ß(3)ARs) in the rat bladder and to examine the contribution of urothelial ß(3)ARs to agonist-induced suppression of bladder reflexes and relaxation of smooth muscle. METHODS: Bladder tissue was collected from 8- to 10-month old female SD rats. In some samples, the urothelium was surgically separated from the smooth muscle. The expression and localization of ßAR mRNA and ß(3)AR protein were determined using RT-PCR and immunohistochemistry. Contractile responses to the specific ß(3)AR agonists TAK-677 and BRL37344 were measured in bladder strips with or without the urothelium. The contribution of urothelial ß(3)ARs to the micturition reflex was assessed in continuous cystometry in urethane anesthetized rats using intravesical delivery of ß(3)AR agonists. RESULTS: RT-PCR detected mRNA of all ßARs in urothelium and smooth muscle. Immunostaining detected ß(3)ARs throughout the urothelium, in the smooth muscle, myofibroblast-like cells, and in the peripheral nerves. Ovariectomy did not change the distribution of ß(3)ARs in any bladder structure. Intravesical administration of TAK-677 and BRL37344 (1-5 × 10(-4) M) decreased voiding frequency and amplitude of bladder contractions. In bladder strips in vitro both ß(3)AR agonists (10(-12) to 10(-4) M) relaxed the smooth muscle in a concentration-dependent manner to the same extent in strips with and without the urothelium. CONCLUSIONS: In addition to their presence in bladder smooth muscle, ß(3)ARs are present in the urothelium where their activation may alter reflex voiding via release of factor(s) that act on non-myocyte structures including the afferent and/or efferent nerves to influence bladder contractility.


Subject(s)
Muscle, Smooth/metabolism , Receptors, Adrenergic, beta-3/metabolism , Urinary Bladder/metabolism , Urothelium/metabolism , Acetates/pharmacology , Adrenergic beta-Agonists/pharmacology , Animals , Ethanolamines/pharmacology , Female , Immunohistochemistry , Indoles/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, beta/metabolism , Receptors, Adrenergic, beta-3/genetics , Reverse Transcriptase Polymerase Chain Reaction , Urinary Bladder/drug effects , Urinary Bladder/physiology , Urination/drug effects , Urothelium/drug effects
19.
Am J Physiol Renal Physiol ; 297(2): F333-40, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19493964

ABSTRACT

Nitric oxide (NO), a neurotransmitter in the lower urinary tract, stimulates soluble guanylyl cyclase (sGC) and in turn cGMP-dependent protein kinase G (PKG) to modulate a number of downstream targets. NO donors reduce bladder hyperactivity in some pathological models but do not affect normal bladder activity in the adult rat. In this study, the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP; 100 microM) decreased the amplitude and frequency of spontaneous and carbachol-enhanced contractions in neonatal rat bladder strips, which are intrinsically hyperactive. This effect was blocked by inhibition of sGC and mimicked by application of a membrane-permeable cGMP analog (8-bromo-cGMP, 100 microM). Inhibition of PKG prevented or reversed the inhibitory effects of 8-bromo-cGMP. A portion of the SNAP-mediated inhibition was also dependent upon PKG; however, a short-lasting, sGC-dependent inhibitory effect of SNAP was still present after PKG inhibition. Inhibition of NO synthase with L-NAME (100 microM) did not change the amplitude or frequency of contractions. However, inhibition of endogenous phosphodiesterase (PDE)-5 with zaprinast (25 microM) reduced the amplitude and frequency of phasic contractions and increased the magnitude of inhibition produced by maximal concentrations of SNAP, suggesting that endogenous PDEs are constitutively active and regulate cGMP production. These results suggest that the NO-cGMP-PKG pathway may be involved in inhibitory control of the neonatal rat bladder.


Subject(s)
Cyclic GMP-Dependent Protein Kinases/metabolism , Cyclic GMP/metabolism , Muscle Contraction , Muscle, Smooth/enzymology , Nitrergic Neurons/metabolism , Nitric Oxide/metabolism , Signal Transduction , Urinary Bladder/enzymology , Animals , Animals, Newborn , Carbachol/pharmacology , Cholinergic Agonists/pharmacology , Cyclic GMP/analogs & derivatives , Cyclic GMP/pharmacology , Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism , Dose-Response Relationship, Drug , Female , Guanylate Cyclase/metabolism , In Vitro Techniques , Male , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/innervation , NG-Nitroarginine Methyl Ester/pharmacology , Neural Inhibition , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase/metabolism , Phosphodiesterase Inhibitors/pharmacology , Protein Kinase Inhibitors/pharmacology , Purinones/pharmacology , Rats , Rats, Sprague-Dawley , S-Nitroso-N-Acetylpenicillamine/pharmacology , Signal Transduction/drug effects , Time Factors , Urinary Bladder/drug effects , Urinary Bladder/innervation
20.
J Pharmacol Exp Ther ; 330(3): 704-17, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19515967

ABSTRACT

Voiding dysfunctions, including increased voiding frequency, urgency, or incontinence, are prevalent in the postmenopausal population. Beta(3)-adrenergic receptor (beta(3)AR) agonists, which relax bladder smooth muscle, are being developed to treat these conditions. We utilized the rat ovariectomy (OVX) model to investigate the effect of ovarian hormone depletion on bladder function and the potential for beta(3)AR agonists to treat bladder hyperactivity in this setting. OVX increased voiding frequency and decreased bladder capacity by approximately 25% in awake rats and induced irregular cystometrograms in urethane-anesthetized rats. Reverse transcription-polymerase chain reaction revealed three betaARs subtypes (beta(1,2,3)) in bladder tissue, and immunostaining indicated beta(3)AR localization in urothelium and detrusor. Receptor expression was not different in OVX and SHAM rats. The beta(3)AR agonist selectivity of BRL37344 [(+/-)-(R(*),R(*))-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid sodium hydrate], TAK-677 [(3-((2R)-(((2R)-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yloxy)acetic acid], and FK175 [acetic acid, 2-[[(8S)-8-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl]oxy], ethyl ester, hydrochloride] was confirmed by examining the relative potency for elevation of cAMP in CHOK1 cells overexpressing the various rat betaARs. Intravenous injection of each of the beta(3)AR agonists (0.1-500 microg/kg) in anesthetized rats decreased voiding frequency, bladder pressure, and amplitude of bladder contractions. In bladder strips, beta(3)AR agonists (10(-12)-10(-4) M) decreased baseline tone and reduced spontaneous contractions. BRL37344 (5 mg/kg) and TAK-677 (5 mg/kg) injected intraperitoneally in awake rats decreased voiding frequency by 40 to 70%. These effects were not altered by OVX. The results indicate that OVX-induced bladder dysfunction, including decreased bladder capacity and increased voiding frequency, is not associated with changes in beta(3)AR expression or the bladder inhibitory effects of beta(3)AR agonists. This suggests that beta(3)AR agonists should prove effective for the treatment of overactive bladder symptoms in the postmenopausal population.


Subject(s)
Adrenergic beta-3 Receptor Agonists , Adrenergic beta-Agonists/pharmacology , Ovariectomy , Urinary Bladder, Neurogenic/drug therapy , Adrenergic beta-Agonists/chemical synthesis , Anesthesia , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclic AMP/metabolism , Female , Humans , Immunohistochemistry , In Vitro Techniques , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, beta-3/biosynthesis , Urinary Bladder, Neurogenic/physiopathology , Urination/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...